Jazz Pharmaceuticals (JAZZ) Stock Forecast, Price Target & Predictions
JAZZ Stock Forecast
Jazz Pharmaceuticals stock forecast is as follows: an average price target of $200.23 (represents a 56.86% upside from JAZZ’s last price of $127.65) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
JAZZ Price Target
The average price target for Jazz Pharmaceuticals (JAZZ) is $200.23 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $250.00 to $169.00. This represents a potential 56.86% upside from JAZZ's last price of $127.65.
JAZZ Analyst Ratings
According to 6 Wall Street analysts, Jazz Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for JAZZ stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Jazz Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 23, 2024 | Daniel Busb | RBC Capital | $179.00 | $113.10 | 58.27% | 40.23% |
| Sep 11, 2024 | Annabel Samimy | Stifel Nicolaus | $230.00 | $105.22 | 118.59% | 80.18% |
| Jun 05, 2024 | Andrea Tan | Goldman Sachs | $169.00 | $104.48 | 61.75% | 32.39% |
| May 02, 2024 | Daniel Busb | RBC Capital | $176.00 | $110.31 | 59.55% | 37.88% |
| Mar 20, 2024 | David Amsellem | Piper Sandler | $188.00 | $124.79 | 50.65% | 47.28% |
| Dec 09, 2022 | - | Goldman Sachs | $190.00 | $150.07 | 26.61% | 48.84% |
| Nov 10, 2022 | - | Goldman Sachs | $192.00 | $149.90 | 28.09% | 50.41% |
| Nov 10, 2022 | - | RBC Capital | $207.00 | $149.90 | 38.09% | 62.16% |
| Jun 20, 2022 | David Amsellem | Piper Sandler | $193.00 | $142.91 | 35.05% | 51.19% |
| Jun 13, 2022 | Ashwani Verma | UBS | $194.00 | $141.59 | 37.02% | 51.98% |
The latest Jazz Pharmaceuticals stock forecast, released on Oct 23, 2024 by Daniel Busb from RBC Capital, set a price target of $179.00, which represents a 58.27% increase from the stock price at the time of the forecast ($113.10), and a 40.23% increase from JAZZ last price ($127.65).
Jazz Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 5 |
| Avg Price Target | $179.00 | $204.50 | $188.40 |
| Last Closing Price | $127.65 | $127.65 | $127.65 |
| Upside/Downside | 40.23% | 60.20% | 47.59% |
In the current month, the average price target of Jazz Pharmaceuticals stock is $179.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 40.23% increase as opposed to Jazz Pharmaceuticals's last price of $127.65. This month's average price target is down -12.47% compared to last quarter, and down -4.99% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 23, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Oct 04, 2024 | Wells Fargo | Buy | Buy | Hold |
| Sep 09, 2024 | UBS | Underperform | Underperform | Hold |
| Sep 09, 2024 | Wells Fargo | Buy | Buy | Hold |
| Aug 23, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 01, 2024 | Wells Fargo | Buy | Buy | Hold |
| Jul 02, 2024 | UBS | Buy | Buy | Hold |
| Jun 06, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jun 05, 2024 | Needham | Underperform | Underperform | Hold |
| Jun 05, 2024 | Piper Sandler | Buy | Buy | Hold |
Jazz Pharmaceuticals's last stock rating was published by RBC Capital on Oct 23, 2024. The company gave JAZZ a "Outperform" rating, the same as its previous rate.
Jazz Pharmaceuticals Financial Forecast
Jazz Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $957.32M | $892.81M | $972.12M | $940.65M | $932.88M | $813.72M | $896.73M | $838.12M | $751.81M | $607.58M | $665.52M | $600.89M | $562.44M | $534.73M | $581.74M | $537.70M | $534.13M | $508.19M | $444.61M | $376.05M |
| Avg Forecast | $1.14B | $1.09B | $1.06B | $995.37M | $1.06B | $1.04B | $1.01B | $953.97M | $1.01B | $968.41M | $941.99M | $897.39M | $975.48M | $939.98M | $902.49M | $852.45M | $864.30M | $832.01M | $731.89M | $609.32M | $638.84M | $577.62M | $503.21M | $544.56M | $560.55M | $523.89M | $508.25M | $465.93M | $414.76M | $380.98M |
| High Forecast | $1.17B | $1.12B | $1.09B | $1.05B | $1.08B | $1.04B | $1.01B | $955.74M | $1.07B | $968.70M | $968.83M | $922.96M | $1.00B | $939.98M | $902.49M | $852.45M | $864.30M | $832.01M | $731.89M | $609.32M | $638.84M | $577.62M | $503.21M | $544.56M | $560.55M | $523.89M | $508.25M | $465.93M | $497.71M | $457.18M |
| Low Forecast | $1.10B | $1.05B | $1.03B | $947.19M | $1.03B | $1.04B | $1.01B | $952.19M | $957.26M | $968.12M | $912.99M | $869.76M | $945.45M | $939.98M | $902.49M | $852.45M | $864.30M | $832.01M | $731.89M | $609.32M | $638.84M | $577.62M | $503.21M | $544.56M | $560.55M | $523.89M | $508.25M | $465.93M | $331.81M | $304.79M |
| # Analysts | 3 | 3 | 3 | 5 | 12 | 6 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.02% | 0.99% | 1.00% | 1.00% | 1.03% | 0.95% | 1.04% | 1.01% | 1.03% | 1.00% | 1.04% | 1.04% | 1.12% | 0.98% | 1.04% | 1.03% | 1.05% | 1.09% | 1.07% | 0.99% |
Jazz Pharmaceuticals's average Quarter revenue forecast for Sep 23 based on 9 analysts is $968.41M, with a low forecast of $968.12M, and a high forecast of $968.70M. JAZZ's average Quarter revenue forecast represents a 1.16% increase compared to the company's last Quarter revenue of $957.32M (Jun 23).
Jazz Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 12 | 6 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 16 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $157.64M | $276.84M | $249.00M | $307.24M | $310.90M | $267.26M | $205.40M | $190.06M | $82.04M | $240.20M | $243.43M | $266.44M | $263.48M | $-123.25M | $235.66M | $197.89M | $266.41M | $192.66M | $142.47M | $163.31M |
| Avg Forecast | $401.33M | $382.65M | $372.92M | $350.80M | $374.32M | $365.31M | $355.94M | $314.37M | $354.77M | $341.30M | $331.99M | $285.79M | $322.60M | $331.28M | $318.07M | $259.81M | $304.61M | $293.23M | $257.94M | $226.60M | $225.15M | $203.57M | $177.35M | $-163.72M | $197.55M | $184.63M | $179.12M | $161.57M | $132.19M | $165.43M |
| High Forecast | $412.77M | $393.55M | $383.55M | $370.32M | $381.31M | $365.63M | $357.20M | $377.25M | $375.84M | $341.40M | $341.45M | $342.95M | $387.12M | $331.28M | $318.07M | $311.78M | $304.61M | $293.23M | $257.94M | $271.92M | $225.15M | $203.57M | $177.35M | $-130.98M | $197.55M | $184.63M | $179.12M | $193.88M | $158.62M | $198.52M |
| Low Forecast | $388.97M | $370.87M | $361.44M | $333.82M | $363.82M | $364.99M | $354.69M | $251.50M | $337.37M | $341.19M | $321.77M | $228.64M | $258.08M | $331.28M | $318.07M | $207.85M | $304.61M | $293.23M | $257.94M | $181.28M | $225.15M | $203.57M | $177.35M | $-196.46M | $197.55M | $184.63M | $179.12M | $129.25M | $105.75M | $132.35M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.47% | 0.97% | 0.77% | 0.93% | 0.98% | 1.03% | 0.67% | 0.65% | 0.32% | 1.06% | 1.08% | 1.31% | 1.49% | 0.75% | 1.19% | 1.07% | 1.49% | 1.19% | 1.08% | 0.99% |
9 analysts predict JAZZ's average Quarter EBITDA for Sep 23 to be $341.30M, with a high of $341.40M and a low of $341.19M. This is 116.51% upper than Jazz Pharmaceuticals's previous annual EBITDA (Jun 23) of $157.64M.
Jazz Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 12 | 6 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 16 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $104.44M | $69.42M | $-239.95M | $-17.10M | $34.66M | $5.79M | $-32.36M | $-52.83M | $-363.32M | $121.83M | $133.41M | $148.23M | $114.80M | $-157.83M | $73.99M | $102.28M | $261.90M | $85.20M | $45.99M | $86.51M |
| Avg Forecast | $373.36M | $364.83M | $336.40M | $291.44M | $374.02M | $347.35M | $310.95M | $2.05M | $327.54M | $311.60M | $280.83M | $1.86M | $176.81M | $324.50M | $290.91M | $1.69M | $252.80M | $231.05M | $244.81M | $114.94M | $295.04M | $283.78M | $216.71M | $-209.66M | $286.90M | $250.30M | $249.22M | $71.45M | $42.69M | $87.61M |
| High Forecast | $387.19M | $378.35M | $348.87M | $356.45M | $389.50M | $348.51M | $315.69M | $2.46M | $349.96M | $312.72M | $291.24M | $2.24M | $212.17M | $324.50M | $290.91M | $2.03M | $252.80M | $231.05M | $244.81M | $137.92M | $295.04M | $283.78M | $216.71M | $-167.73M | $286.90M | $250.30M | $249.22M | $85.74M | $51.23M | $105.13M |
| Low Forecast | $358.42M | $350.23M | $322.94M | $198.58M | $359.78M | $346.19M | $306.21M | $1.64M | $305.12M | $310.48M | $269.59M | $1.49M | $141.44M | $324.50M | $290.91M | $1.36M | $252.80M | $231.05M | $244.81M | $91.95M | $295.04M | $283.78M | $216.71M | $-251.59M | $286.90M | $250.30M | $249.22M | $57.16M | $34.15M | $70.09M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.37% | 37.25% | -1.36% | -0.05% | 0.12% | 3.42% | -0.13% | -0.23% | -1.48% | 1.06% | 0.45% | 0.52% | 0.53% | 0.75% | 0.26% | 0.41% | 1.05% | 1.19% | 1.08% | 0.99% |
Jazz Pharmaceuticals's average Quarter net income forecast for Sep 23 is $311.60M, with a range of $310.48M to $312.72M. JAZZ's average Quarter net income forecast represents a 198.36% increase compared to the company's last Quarter net income of $104.44M (Jun 23).
Jazz Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 12 | 6 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 16 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $340.84M | $297.92M | $383.20M | $358.48M | $366.47M | $308.81M | $398.46M | $363.68M | $429.03M | $260.51M | $247.17M | $207.25M | $191.41M | $208.40M | $214.28M | $178.71M | $176.01M | $167.95M | $207.21M | $144.25M |
| Avg Forecast | $431.10M | $411.03M | $400.59M | $376.82M | $402.09M | $392.42M | $382.35M | $384.37M | $381.09M | $366.62M | $356.62M | $349.43M | $327.56M | $355.85M | $341.66M | $317.66M | $327.20M | $314.98M | $277.08M | $245.76M | $241.85M | $218.68M | $190.51M | $276.83M | $212.21M | $198.33M | $192.41M | $140.84M | $192.31M | $146.10M |
| High Forecast | $443.39M | $422.75M | $412.01M | $397.79M | $409.60M | $392.76M | $383.70M | $461.24M | $403.73M | $366.73M | $366.78M | $419.31M | $393.07M | $355.85M | $341.66M | $381.19M | $327.20M | $314.98M | $277.08M | $294.91M | $241.85M | $218.68M | $190.51M | $332.20M | $212.21M | $198.33M | $192.41M | $169.01M | $230.77M | $175.33M |
| Low Forecast | $417.83M | $398.38M | $388.26M | $358.59M | $390.81M | $392.07M | $381.00M | $307.49M | $362.40M | $366.51M | $345.64M | $279.54M | $262.05M | $355.85M | $341.66M | $254.13M | $327.20M | $314.98M | $277.08M | $196.61M | $241.85M | $218.68M | $190.51M | $221.46M | $212.21M | $198.33M | $192.41M | $112.67M | $153.84M | $116.88M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.96% | 0.85% | 1.17% | 1.01% | 1.07% | 0.97% | 1.22% | 1.15% | 1.55% | 1.06% | 1.02% | 0.95% | 1.00% | 0.75% | 1.01% | 0.90% | 0.91% | 1.19% | 1.08% | 0.99% |
Jazz Pharmaceuticals's average Quarter SG&A projection for Sep 23 is $366.62M, based on 9 Wall Street analysts, with a range of $366.51M to $366.73M. The forecast indicates a 7.56% rise compared to JAZZ last annual SG&A of $340.84M (Jun 23).
Jazz Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 12 | 6 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 16 |
| EPS | - | - | - | - | - | - | - | - | - | - | $1.63 | $1.09 | $-3.81 | $-0.27 | $0.56 | $0.09 | $-0.53 | $-0.86 | $-6.11 | $2.16 | $2.39 | $2.67 | $2.07 | $-2.82 | $1.31 | $1.80 | $4.62 | $1.49 | $0.77 | $1.44 |
| Avg Forecast | $5.91 | $5.78 | $5.33 | $4.61 | $5.92 | $5.50 | $4.92 | $4.18 | $5.18 | $4.93 | $4.45 | $4.24 | $0.88 | $4.66 | $4.18 | $3.84 | $3.63 | $3.32 | $3.52 | $3.73 | $4.24 | $4.08 | $3.11 | $0.64 | $4.12 | $3.60 | $3.58 | $3.16 | $2.58 | $2.37 |
| High Forecast | $6.13 | $5.99 | $5.52 | $5.64 | $6.17 | $5.52 | $5.00 | $4.19 | $5.54 | $4.95 | $4.61 | $4.40 | $0.92 | $4.66 | $4.18 | $3.84 | $3.63 | $3.32 | $3.52 | $3.73 | $4.24 | $4.08 | $3.11 | $0.64 | $4.12 | $3.60 | $3.58 | $3.16 | $3.10 | $2.84 |
| Low Forecast | $5.67 | $5.54 | $5.11 | $3.14 | $5.70 | $5.48 | $4.85 | $4.17 | $4.83 | $4.91 | $4.27 | $4.07 | $0.85 | $4.66 | $4.18 | $3.84 | $3.63 | $3.32 | $3.52 | $3.73 | $4.24 | $4.08 | $3.11 | $0.64 | $4.12 | $3.60 | $3.58 | $3.16 | $2.06 | $1.90 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.37% | 0.26% | -4.32% | -0.06% | 0.13% | 0.02% | -0.15% | -0.26% | -1.74% | 0.58% | 0.56% | 0.66% | 0.67% | -4.42% | 0.32% | 0.50% | 1.29% | 0.47% | 0.30% | 0.61% |
According to 9 Wall Street analysts, Jazz Pharmaceuticals's projected average Quarter EPS for Sep 23 is $4.93, with a low estimate of $4.91 and a high estimate of $4.95. This represents a 202.60% increase compared to JAZZ previous annual EPS of $1.63 (Jun 23).
Jazz Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| APLS | Apellis Pharmaceuticals | $28.25 | $74.50 | 163.72% | Buy |
| LRMR | Larimar Therapeutics | $7.94 | $20.33 | 156.05% | Buy |
| RARE | Ultragenyx Pharmaceutical | $48.71 | $106.93 | 119.52% | Buy |
| LEGN | Legend Biotech | $39.35 | $82.69 | 110.14% | Buy |
| VRDN | Viridian Therapeutics | $22.48 | $37.92 | 68.68% | Buy |
| LQDA | Liquidia | $10.27 | $17.17 | 67.19% | Buy |
| JAZZ | Jazz Pharmaceuticals | $127.65 | $200.23 | 56.86% | Buy |
| BMRN | BioMarin Pharmaceutical | $66.66 | $101.70 | 52.57% | Buy |
| ASND | Ascendis Pharma | $126.03 | $190.21 | 50.92% | Buy |
| DNLI | Denali Therapeutics | $29.63 | $40.00 | 35.00% | Buy |
| PCVX | Vaxcyte | $96.63 | $124.00 | 28.32% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| TECH | Bio-Techne | $75.93 | $91.69 | 20.76% | Buy |
| PTGX | Protagonist Therapeutics | $42.67 | $50.00 | 17.18% | Buy |
| BPMC | Blueprint Medicines | $96.88 | $109.71 | 13.24% | Buy |
| INCY | Incyte | $80.48 | $84.56 | 5.07% | Buy |
| HALO | Halozyme Therapeutics | $58.61 | $56.86 | -2.99% | Buy |
| ALNY | Alnylam Pharmaceuticals | $264.60 | $254.21 | -3.93% | Buy |
| UTHR | United Therapeutics | $400.45 | $358.20 | -10.55% | Buy |
| EXEL | Exelixis | $35.19 | $30.50 | -13.33% | Buy |
| ARGX | argenx SE | $599.35 | $475.14 | -20.72% | Buy |